## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.32 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($12.76)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 2)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Acadia Healthcare Company, Inc. (ACHC) And Encourages Investors to Connect**
- Source: KSNT 27 News | 20251221T210954 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Acadia Healthcare Company, Inc. (ACHC) concerning alleged corporate wrongdoing by its officers and/or directors. The firm encourages investors who purchased Acadia Healthcare securities before February 28, 2020, and still hold them, to connect with their investigation. They represent investors on a contingency fee basis and only seek reimbursement for expenses and fees if successful.

**2. Bronstein, Gewirtz & Grossman, LLC Is Investigating Acadia Healthcare Company, Inc. (ACHC) And Encourages Investors to Connect**
- Source: FOX 2 | 20251221T110000 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Healthcare Company, Inc. (ACHC) securities. The investigation focuses on whether Acadia Healthcare engaged in corporate wrongdoing. Investors who acquired ACHC shares before February 28, 2020, are encouraged to contact the firm to assist in the investigation.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 9)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $17 | $22 | -23% |
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (18.7%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 35.6% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (9 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 18.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.3 |
| Current P/E | 6.9 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_20 stable at -4.7% (minimal 5-day change). Below STRENGTH zone by 8.7pp (needs >4.0% for momentum thesis). AM_20 at -4.1% indicates price below own 20MA trend. Underperforming sector by 4.5pp, stock-specific weakness. Below SMA200 (0.64x), long-term trend not supportive. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.68% (CS: 10) | Weak |
| RSI_14 | 37.1 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 0.959x | Below |
| vs SMA50 | 0.788x | Below |
| vs SMA200 | 0.644x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $14.46
- **Stop Loss:** $12.76 (11.8% risk)
- **Target:** $17.86 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 705
- **Position Value:** $10,194.30
- **Portfolio %:** 10.19%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*